Physician

Pamela Recktenwald Sinclair, MD

According to 2025 Medicare claims, Pamela Sinclair, MD (NPI: 1972678571) practices medical oncology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from York, SC. This provider's primary affiliated billing organization is THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (NPI: 1306269691; TIN: 56-0529945) and primary practice location at 29732-1724. Sinclair is affiliated with the Carolinas HealthCare System ACO, LLC (ACO ID: A3675), participating under the MSSP model.

Sinclair's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 886 traditional Medicare patients, billed 168,936 HCPCS/CPT codes, and received $2,944,756 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,466 prescription claims across 418 beneficiaries totaling $4,804,018 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 35 claims. Open Payments data shows 10 records totaling $1,041. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,165,775 to $2,944,756. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,819,496 to $4,804,018. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $6,769 and ending at $1,655.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	662	125,125	$1,165,775
2016	672	140,146	$1,704,070
2017	719	130,568	$1,737,342
2018	737	165,348	$2,323,676
2019	742	204,107	$2,410,919
2020	796	211,290	$2,502,125
2021	890	241,516	$3,367,885
2022	767	168,887	$2,699,183
2023	850	194,274	$2,672,074
2024	886	168,936	$2,944,756

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	303	2,170	$1,819,496
2016	318	2,349	$1,869,200
2017	351	2,776	$2,423,118
2018	380	2,877	$2,971,183
2019	360	2,485	$3,318,261
2020	373	2,347	$2,741,985
2021	398	2,341	$3,061,847
2022	384	2,114	$3,511,350
2023	425	2,296	$4,250,458
2024	418	2,466	$4,804,018

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	20	75	$6,465
2016	12	70	$4,095
2017	35	47	$7,143
2018	36	52	$7,436
2019	13	13	$1,570
2020	12	44	$4,504
2021	15	79	$5,676
2022	27	73	$7,113
2023	29	73	$11,791
2024	N/R	35	$2,140

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	122	388	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	440	714	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	273	489	$60
80053	Blood test, comprehensive group of blood chemicals	619	1,591	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	701	1,760	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	123	3,518	$2,007,334
Lenalidomide	Lenalidomide	42	1,169	$576,874
Tagrisso	Osimertinib Mesylate	20	600	$340,561
Ibrance	Palbociclib	14	399	$216,456
Votrient	Pazopanib Hcl	11	330	$165,600

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	13	$1,480
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$453
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$1,041	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Pamela Recktenwald Sinclair, MD?

Tedicare shows public-source Medicare data for Pamela Recktenwald Sinclair, MD (NPI 1972678571), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Pamela Recktenwald Sinclair, MD have ACO affiliation data?

Pamela Recktenwald Sinclair, MD is shown with ACO affiliation data for Carolinas HealthCare System ACO, LLC (MSSP, ACO ID A3675).

What billing organization is linked to Pamela Recktenwald Sinclair, MD?

Pamela Recktenwald Sinclair, MD is linked to THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (billing NPI 1306269691) in the available physician profile data.

Does Pamela Recktenwald Sinclair, MD have Open Payments data?

Pamela Recktenwald Sinclair, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.